Caffeine and Methylliberine: A Human Pharmacokinetic Interaction Study | | 2022 |
Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects | Clinical and Translational Science | 2021 |
Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib | Frontiers in Pharmacology | 2021 |
In Vitro/In Vivo Correlation for Drug-Drug Interactions | | 2020 |
Non-vitamin K antagonist oral anticoagulants and sport | Minerva Cardioangiologica | 2020 |
HPLC methods of fexofenadine quantitative analysis in rabbits’ liver | Farmatsiya I Farmakologiya | 2020 |
Strategies for Incorporating Pharmacokinetic Studies into Oncology Phase I Trials | | 2020 |
The possibility of prognosis of progesterone preparations interaction | Russian Journal of Human Reproduction | 2018 |
6. Role of Regulatory Science in New Drug Evaluation : Clinical Pharmacology and Pharmacokinetics | Japanese Journal of Clinical Pharmacology and Therapeutics | 2018 |
Some Methodologic Considerations in the Assessment of Methods for Predicting Pharmacokinetic Drug-Drug Interactions | Clinical Pharmacology in Drug Development | 2017 |
INFLUENCE OF VILDAGLIPTIN AND GLIQUIDONE COMBINATION ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY AND EXPRESSION ON THE BACKGROUND OF NORM AND IN EXPERIMENTAL ALLOXAN-INDUCED DIABETES MELLITUS TYPE 2 | I P Pavlov Russian Medical Biological Herald | 2016 |
IN SILICO MODELING OF METABOLITE KINETICS | | |
Views on the Therapeutic Needs of Older Adults | AAPS Advances in the Pharmaceutical Sciences Series | 2016 |
Summary Report of Questionnaire Survey on Current Situation and Issues of Human Mass Balance Study Using Radioisotopes in Japan | Japanese Journal of Clinical Pharmacology and Therapeutics | 2015 |
Renal Organic Cation and Anion Transport: From Physiology to Genes☆ | | 2014 |
Evaluation of Time-Dependent CYP3A4 Inhibition Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP) | Methods in Pharmacology and Toxicology | 2014 |
In Vitro CYP Induction Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
In Vitro Characterization of Renal Transporters OAT1, OAT3, and OCT2 | Methods in Pharmacology and Toxicology | 2014 |
Membrane Transporters in ADME | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
In Vitro Kinetic Characterization of Transporter-Mediated Permeability | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
Drug-transporter interaction testing in drug discovery and development | World Journal of Pharmacology | 2013 |
Pharmacokinetic drug interactions in liver disease: An update | World Journal of Gastroenterology | 2016 |
Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism | Current Drug Metabolism | 2019 |
Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients | PLoS ONE | 2016 |
Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3 | Clinical and Translational Science | 2019 |
Irreversible enzyme inhibition kinetics and drug-drug interactions | Methods in Molecular Biology | 2014 |
Reversible mechanisms of enzyme inhibition and resulting clinical significance | Methods in Molecular Biology | 2014 |
Case study 4. Predicting the drug interaction potential for inhibition of CYP2C8 by montelukast | Methods in Molecular Biology | 2014 |
Pharmacokinetics and ADME characterizations of antibody-drug conjugates | Methods in Molecular Biology | 2013 |
Pharmacogenetics of membrane transporters: a review of current approaches | Methods in Molecular Biology | 2014 |
Prediction of Hepatic Transporter-Mediated Drug–Drug Interaction from In Vitro Data | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
The Role of Transporters in Drug Development: Regulatory Science Perspectives from the FDA | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
INTEGRATED REACTIVE METABOLITE STRATEGIES | | |
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects | European Journal of Clinical Pharmacology | 2021 |
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator | Clinical Pharmacology in Drug Development | 2020 |
Drug Interactions in the Liver | | 2020 |
Replacing the eleven native tryptophans by directed evolution produces an active P-glycoprotein with site-specific, non-conservative substitutions | Scientific Reports | 2020 |
Induction of Cytochrome P450 Systems | | 2020 |
Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin | Scientific Reports | 2020 |
Drug–Drug Interaction Studies | | 2020 |
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6 | Pharmacology Research and Perspectives | 2020 |
Update on Therapeutic Protein-Drug Interaction: Information in Labeling | Clinical Pharmacokinetics | 2020 |
Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans | Clinical and Translational Science | 2019 |
Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[C]Methylpurine in Mice | Molecular Imaging and Biology | 2019 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis | Clinical Pharmacokinetics | 2019 |
Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects | Antimicrobial Agents and Chemotherapy | 2019 |
Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam | CPT: Pharmacometrics and Systems Pharmacology | 2019 |
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects | Clinical Drug Investigation | 2019 |
EASL Clinical Practice Guidelines: Drug-induced liver injury | Journal of Hepatology | 2019 |
Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers | European Journal of Clinical Pharmacology | 2019 |
Considerations for Biologic Product Drug-Drug Interactions: A Regulatory Perspective | Clinical Pharmacology and Therapeutics | 2019 |
Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers | Clinical and Translational Science | 2019 |
Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment | European Journal of Clinical Pharmacology | 2019 |
Does In Vitro Cytochrome P450 Downregulation Translate to In Vivo Drug-Drug Interactions? Preclinical and Clinical Studies With 13-cis-Retinoic Acid | Clinical and Translational Science | 2019 |
A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin | Clinical Pharmacology and Therapeutics | 2019 |
Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction | CPT: Pharmacometrics and Systems Pharmacology | 2019 |
Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects | Clinical Pharmacokinetics | 2019 |
FDA Public Meeting Report on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications" | Journal of Clinical Pharmacology | 2018 |
In Vitro/In Vivo Correlation for Drug-Drug Interactions | | 2018 |
Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects | Journal of Clinical Pharmacology | 2018 |
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy | British Journal of Clinical Pharmacology | 2018 |
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans | British Journal of Clinical Pharmacology | 2018 |
Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro | Molecular Pharmaceutics | 2018 |
A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide | CPT: Pharmacometrics and Systems Pharmacology | 2018 |
Drug Interactions With New Synthetic Opioids | Frontiers in Pharmacology | 2018 |
Experimental Studies of the Effects of Progesterone on the Functional Activity of P-Glycoprotein | Pharmaceutical Chemistry Journal | 2018 |
Renal Organic Cation and Anion Transport: From Physiology to Genes | | 2018 |
In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor | Clinical Pharmacology in Drug Development | 2018 |
Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers | Paediatric Drugs | 2018 |
Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling | Basic and Clinical Pharmacology and Toxicology | 2018 |
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies | Investigational New Drugs | 2018 |
Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin | Xenobiotica | 2018 |
Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review | American Journal of Obstetrics and Gynecology | 2018 |
In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes | Xenobiotica | 2018 |
Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail | European Journal of Drug Metabolism and Pharmacokinetics | 2018 |
In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450 | Xenobiotica | 2018 |
Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition | Xenobiotica | 2018 |
Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge | Methods in Pharmacology and Toxicology | 2018 |
Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters | Journal of Clinical Pharmacology | 2018 |
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects | Drugs in R and D | 2018 |
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development | Clinical and Translational Science | 2018 |
In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics | European Journal of Clinical Pharmacology | 2018 |
Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs | British Journal of Clinical Pharmacology | 2018 |
Pharmacokinetic Drug Interaction Study of Bazedoxifene and Ibuprofen | Clinical Pharmacology in Drug Development | 2018 |
Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics | Clinical Pharmacokinetics | 2018 |
Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin | Clinical and Translational Science | 2018 |
Bidirectional Pharmacokinetic Interaction Between Amodiaquine and Pioglitazone in Healthy Subjects | Journal of Clinical Pharmacology | 2018 |
The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects | Pharmacology Research and Perspectives | 2018 |
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects | European Journal of Drug Metabolism and Pharmacokinetics | 2018 |
Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance | Journal of Clinical Pharmacology | 2018 |
The Role of Transporters in Drug Accumulation and Mitochondrial Toxicity | | 2018 |
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection | PLoS ONE | 2017 |
Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics | Drug Safety - Case Reports | 2017 |
Validation of a total IC method which enables in vitro assessment of transporter inhibition under semi-physiological conditions | Xenobiotica | 2017 |
Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies | Journal of Clinical Pharmacology | 2017 |
Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver | Xenobiotica | 2017 |
Metabolic profile and pharmacokinetics of polyphyllin I, an anticancer candidate, in rats by UPLC-QTOF-MS/MS and LC-TQ-MS/MS | Biomedical Chromatography | 2017 |
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Journal of Clinical Pharmacology | 2017 |
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib | Clinical Pharmacokinetics | 2017 |